Timothy Rolph, the Chief Scientific Officer of $AKRO ($AKRO), sold 2,450 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing ...
In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Akero Therapeutics (AKRO – Research Report), with a price target of $35.00. The company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback